4.6 Review

Systematic review: Histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative

Journal

JOURNAL OF CROHNS & COLITIS
Volume 8, Issue 12, Pages 1582-1597

Publisher

OXFORD UNIV PRESS
DOI: 10.1016/j.crohns.2014.08.011

Keywords

Inflammatory bowel disease; Ulcerative colitis; Histology; Histological healing; Histological indices; Mucosal healing

Funding

  1. Inflammatory Bowel Disease

Ask authors/readers for more resources

Background and aims: Advances in the medical management of inflammatory bowel disease (IBD) have altered treatment targets. Endoscopic mucosal healing is associated with better outcomes in IBD, though less is known about the significance of achieving histological remission. Our aim was to perform a systematic review to investigate whether histological or 'complete' remission constitutes a further therapeutic target in IBD. Methods: A bibliographic search was performed on the 1st of October 2013 and subsequently on the 1st of March 2014 of online databases (OVID SP MEDLINE, OVID EMBASE, National Pubmed Central Medline, Cochrane Library, ISI, conference abstracts), using MeSH terms and key words: (inflammatory bowel diseases OR crohn disease OR ulcerative colitis OR colitis) AND (mucosal healing OR histological healing OR pathological healing OR histological scoring OR pathological scoring). Results: The search returned 2951 articles. 120 articles were cited in the final analysis. There is no validated definition of histological remission in IBD. There are 22 different histological scoring systems for IBD, none of which are fully validated. Microscopic inflammation persists in 16-100% of cases of endoscopically quiescent disease. There is evidence that histological remission may predict risk of complications in ulcerative colitis beyond endoscopic mucosal healing, though data are scarce in Crohn's disease. Conclusions: Histological remission in IBD represents a target distinct from endoscopic mucosal healing, not yet routinely sought in clinical trials or practice. There remains a need for a standardized and validated histological scoring system and to confirm the prognostic value of histological remission as a treatment target in IBD. (C) 2014 Published by Elsevier B.V. on behalf of European Crohn's and Colitis Organisation. This is an open access article under the CC BY-NC-ND license.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available